Background. Candidemia contributes to prolonged hospitalizations, increased cost, and increased morbidity and mortality. Obesity worsens clinical outcomes for bacterial infections, though little is known about fungal infections. The purpose of this study was to assess if clinical outcomes differ in obese vs. non-obese patients with candidemia.
Background. Obese patients may have altered pharmacokinetic parameters when compared with normal weight patients due to their body habitus and altered drug clearance. Case reports suggest higher echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. The purpose of this project is to compare patient outcomes between normal weight and overweight patients that receive an echinocandin for candidemia.
Methods. IRB approved, retrospective cohort at five hospitals with an antimicrobial stewardship program. Dates: January 1, 2014-January 31, 2018. Included: ≥18 years, Candida species positive blood culture or T2MR, anidulafungin FDA label dose for ≥72 hours. Exclusion criteria: neutropenia, endocarditis, osteomyelitis, meningitis, immunosuppression. Primary outcome: 30-day all-cause mortality. Secondary outcomes: 14-day global clinical cure rates, Candida eye involvement, recurrence, antifungal restart, and optimal azole dose.
Results. One hundred seventy-three patients included: 121 blood; 73 T2MR. Obese: more female, pulmonary disease. Underweight: less surgery. Most common species: C. albicans (33%), C. glabrata (33%). More C. parapsilosis in obese (36.4%). Low anidulafungin minimum inhibitory concentrations (MIC) in all groups, but elevated in C. parapsilosis. No association between body mass index and mortality: underweight (36.4%), normal (25.8%), overweight (32.0%), obese (33.9%), morbidly obese (31.8%). See Table 1 for variables associated with mortality. No differences in quality of management, recurrence, Candida eye involvement, antifungal restart, optimal azole dose. More global cure in survivors.
Conclusion. We were unable to detect a difference in mortality in patients with candidemia by weight group. Line removal and receipt of ≥5 days of anidulafungin were protective. Methods. We reviewed blood culture results (January 1, 2010-December 31, 2017), selected patients with candidemia, defined the place of onset (community onset [CO]: 0-3 days after admission; hospital onset [HO]: ≥4 days), the source and species distribution and compared CO and HO cases.
Results. We encountered 210 candidemia episodes. The rate of candidemia (0.6-1.2/1,000 discharges) and species distribution fluctuated without a clear trend. CO accounted for 92 (43.8%) episodes including 83 healthcare-related (CO-HC) and 9 (4.3%) without healthcare exposure (CO-A). CO/HO proportion did not significantly change over time. Source and species distribution were similar in CO and HO cases except for higher proportion of intravenous drug users (IVDA), soft tissue/bone (STB) sources, and a trend toward more UTI in CO (table) . Comparison of cases with C. albicans and C. glabrata revealed that C. glabrata was more common in diabetics (51.5 vs. 33.0%; P = 0.005), and hemodialysis-dependent (H-D) cases (63.6% vs. 38.5; P = 0.04), and tended to be less common in UTI (25.9% vs. 45.4% in other sources; P = 0.09).
Conclusion. Candidemia remains a healthcare-related event but a significant portion is CO. CO-A is limited to IVDA and patients with comorbidities. Sources and species distribution was similar in CO-HC and HO cases except for more UTI in CO-HC. C. albicans remained more common but C. glabrata surpassed C. albicans among diabetics and H-D. 
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No reported disclosures. Background. Early initiation of empiric antifungal therapy has been shown to decrease morbidity and mortality among patients with candidemia/invasive candidiasis (C/IC). However, the initiation of appropriate antifungal therapy is frequently delayed due to the severe limitations in early diagnosis. The goal of this study is to develop a high-risk scoring system to identify patients who may be eligible for preemptive antifungal therapy. The proposed new methodology combines hybrid modeling and blockchain technology.
Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
Methods. Our approach is novel and using expert physicians' perception of C/ IC risk factors with those described in the hospitals through a set of models (hybrid model building from primary and secondary data). The goal is to improve the early detection of C/IC and initiate antifungal therapy. Once candidate hybrid models are derived, blockchain technology will be utilized. The methodology is based on vectors consisting of the ranking of candidiasis risk factors. These vectors will be constructed based on expert clinicians rank scores of known risk factors. Such methods are different than the usual statistical rank correlation computations, such as Spearman's rank correlation, etc
Results. Preliminary analysis suggests threepotential models. Model 1: uses the following order of variables, by their relative importance: (1) major surgery within 0-3 days, (2)TPN-7-3 days, (3) steroids 0-3 days, (4) ECMO, (5) hemodialysis 0-3 days, (6) diabetes mellitus. Model 2 includes: (1)multifocal Candida colonization, 2.) central venous catheter 0-3 days, (3) LVAD, (4) medical ICU, (5) APACHE score > 20, (6) mechanical ventilation. Model 3 includes (1) pancreatitis -710 days, (2) diabetes mellitus, (3) hemodialysis 0-3 days, (4) central venous catheter 0-3 days, (5) TPN-7-3 days, 6.) APACHE score > 20.
Conclusion. Blockchain methods we propose are some of the first of their kind used in health research and are very suitable for the early detection of C/IC and other diseases where preemptive therapy is necessary. The following step will be to verify and use these models in the clinical realm and verify their effects on outcomes. Second we need to develop and evaluate our proposed methodology in building hybrid models,
